• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝癌肝动脉灌注化疗与经动脉化疗栓塞术的辐射剂量比较。

Comparison of radiation doses between hepatic artery infusion chemotherapy and transarterial chemoembolization for liver cancer.

作者信息

Yuan Hui, Lu Hailei, Zeng Jiahuan, Zhang Yan, Shen Lujun

机构信息

Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People's Republic of China.

State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou, 510060, People's Republic of China.

出版信息

J Interv Med. 2021 Aug 13;4(4):184-189. doi: 10.1016/j.jimed.2021.08.004. eCollection 2021 Nov.

DOI:10.1016/j.jimed.2021.08.004
PMID:35586376
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8947989/
Abstract

OBJECTIVE

To analyze the radiation dose received by patients during hepatic artery infusion chemotherapy (HAIC) and transarterial chemoembolization (TACE) procedures and the related influencing factors.

METHODS

Data of 162 cases in the HAIC group and 230 cases in the TACE group were collected. The included covariates were Age (<45/45-59/≥60 years), BMI levels (underweight/normal weight/obesity), focus Dye of tumor (present/absent), lesion size (<5cm/≥5cm), superselection (present/absent), hepatic vascular variation (present/absent). The endpoints were postoperative dose-area product (DAP), exposure time and Air kerma (AK).

RESULTS

Of all included patients, the HAIC group patients were younger than those in the TACE group (P ​= ​0.028). The proportion of patients with large lesions in the HAIC group was higher than the TACE group (45.7% vs. 33.9%, P ​= ​0.019). The proportion of patients who had superselection was lower in the HAIC group as compared to the TACE group (61.7% vs. 82.2%, P ​< ​0.001). Generally, the HAIC group has lower DAP, exposure time and AK by 36.3% (P ​< ​0.001), 38.2% (P ​< ​0.001), and 41.3% (P ​< ​0.001) than the TACE group, respectively. Linear regression analysis showed the procedure method (HAIC/TACE, P ​< ​0.001), type of DSA machine (Pheno/FD20, P ​< ​0.001), BMI levels (P ​< ​0.001), age (P ​= ​0.021), lesion size (<5cm/≥5 ​cm, P ​= ​0.031) significantly correlated with low DAP. In the HAIC group, the type of DSA machine and BMI correlated with the radiation dose, while in the TACE group, the type of DSA machine, BMI, and lesion size correlated with the radiation dose.

CONCLUSION

Compared with TACE, HAIC enables doctors and patients to receive lower radiation doses. Obese patients in both HAIC and TACE groups increase the radiation exposure in interventional doctors and patients, but large lesions only affect the radiation dose in the TACE procedure.

摘要

目的

分析肝动脉灌注化疗(HAIC)和经动脉化疗栓塞术(TACE)过程中患者接受的辐射剂量及其相关影响因素。

方法

收集HAIC组162例和TACE组230例的数据。纳入的协变量包括年龄(<45/45 - 59/≥60岁)、体重指数水平(体重过轻/正常体重/肥胖)、肿瘤病灶染色(有/无)、病变大小(<5cm/≥5cm)、超选择(有/无)、肝血管变异(有/无)。观察终点为术后剂量面积乘积(DAP)、曝光时间和空气比释动能(AK)。

结果

在所有纳入患者中,HAIC组患者比TACE组患者年轻(P = 0.028)。HAIC组大病灶患者比例高于TACE组(45.7%对33.9%,P = 0.019)。HAIC组超选择患者比例低于TACE组(61.7%对82.2%,P < 0.001)。总体而言,HAIC组的DAP、曝光时间和AK分别比TACE组低36.3%(P < 0.001)、38.2%(P < 0.001)和41.3%(P < 0.001)。线性回归分析显示,手术方法(HAIC/TACE,P < 0.001)、DSA机器类型(Pheno/FD20,P < 0.001)、体重指数水平(P < 0.001)、年龄(P = 0.021)、病变大小(<5cm/≥5cm,P = 0.031)与低DAP显著相关。在HAIC组中,DSA机器类型和体重指数与辐射剂量相关,而在TACE组中,DSA机器类型、体重指数和病变大小与辐射剂量相关。

结论

与TACE相比,HAIC可使医生和患者接受更低的辐射剂量。HAIC组和TACE组中的肥胖患者均增加了介入医生和患者的辐射暴露,但大病灶仅影响TACE手术中的辐射剂量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f337/8947989/fadde100cddd/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f337/8947989/ddfebb1843be/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f337/8947989/e6dcc4216ed0/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f337/8947989/947ca2484d21/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f337/8947989/fadde100cddd/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f337/8947989/ddfebb1843be/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f337/8947989/e6dcc4216ed0/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f337/8947989/947ca2484d21/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f337/8947989/fadde100cddd/gr4.jpg

相似文献

1
Comparison of radiation doses between hepatic artery infusion chemotherapy and transarterial chemoembolization for liver cancer.肝癌肝动脉灌注化疗与经动脉化疗栓塞术的辐射剂量比较。
J Interv Med. 2021 Aug 13;4(4):184-189. doi: 10.1016/j.jimed.2021.08.004. eCollection 2021 Nov.
2
Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.使用改良FOLFOX方案的肝动脉灌注化疗与经动脉化疗栓塞术治疗巨大不可切除肝细胞癌的前瞻性非随机研究。
Chin J Cancer. 2017 Oct 23;36(1):83. doi: 10.1186/s40880-017-0251-2.
3
Hepatic arterial infusion chemotherapy for hepatocellular carcinoma refractory to transarterial chemoembolization: exploring the influence of prior transarterial chemoembolization and additional transarterial chemoembolization on survival outcomes.经动脉化疗栓塞难治性肝细胞癌的肝动脉灌注化疗:探讨既往经动脉化疗栓塞及额外经动脉化疗栓塞对生存结局的影响。
J Gastrointest Oncol. 2024 Apr 30;15(2):721-729. doi: 10.21037/jgo-23-1006. Epub 2024 Apr 26.
4
A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma.使用阿霉素进行高剂量肝动脉灌注化疗与经动脉化疗栓塞治疗难治性晚期肝细胞癌的对比研究。
Korean J Hepatol. 2010 Dec;16(4):355-61. doi: 10.3350/kjhep.2010.16.4.355.
5
Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma.经肝动脉化疗栓塞术联合肝动脉灌注化疗加 S-1 治疗肝细胞癌。
World J Gastroenterol. 2020 Jul 21;26(27):3975-3988. doi: 10.3748/wjg.v26.i27.3975.
6
Survival Comparisons of Hepatic Arterial Infusion Chemotherapy With mFOLFOX and Transarterial Chemoembolization in Patients With Unresectable Intrahepatic Cholangiocarcinoma.肝动脉灌注化疗联合mFOLFOX与经动脉化疗栓塞术治疗不可切除性肝内胆管癌患者的生存比较
Front Oncol. 2021 Apr 1;11:611118. doi: 10.3389/fonc.2021.611118. eCollection 2021.
7
Prognostic factors for transarterial chemoembolization combined with sustained oxaliplatin-based hepatic arterial infusion chemotherapy of colorectal cancer liver metastasis.经动脉化疗栓塞联合基于奥沙利铂的持续肝动脉灌注化疗治疗结直肠癌肝转移的预后因素。
Chin J Cancer Res. 2017 Feb;29(1):36-44. doi: 10.21147/j.issn.1000-9604.2017.01.05.
8
Radiation exposure during TACE procedures using additional cone-beam CT (CBCT) for guidance: safety and precautions.在使用附加锥形束CT(CBCT)进行引导的经动脉化疗栓塞(TACE)手术过程中的辐射暴露:安全性及注意事项。
Acta Radiol. 2018 Nov;59(11):1277-1284. doi: 10.1177/0284185118761203. Epub 2018 Feb 28.
9
Operator radiation dose during trans-hepatic arterial chemoembolization: different patients' positions via transradial or transfemoral access.经桡动脉或股动脉入路行肝动脉化疗栓塞术时的术者辐射剂量:不同患者体位。
Diagn Interv Radiol. 2022 Jul;28(4):376-382. doi: 10.5152/dir.2022.211327.
10
Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.奥沙利铂联合氟尿嘧啶肝动脉灌注化疗与经肝动脉化疗栓塞/栓塞治疗合并主门静脉癌栓的中晚期肝癌的疗效比较
Cardiovasc Intervent Radiol. 2020 Jul;43(7):996-1005. doi: 10.1007/s00270-019-02406-3. Epub 2020 Jan 23.

引用本文的文献

1
Transarterial Chemoembolization Plus Sorafenib versus Transarterial Chemoembolization Alone for Advanced Hepatocellular Carcinoma: An Umbrella Review of Meta-Analyses and Systematic Reviews.经动脉化疗栓塞联合索拉非尼与单纯经动脉化疗栓塞治疗晚期肝细胞癌:Meta分析和系统评价的伞状综述
J Hepatocell Carcinoma. 2023 Oct 5;10:1723-1733. doi: 10.2147/JHC.S429352. eCollection 2023.
2
Radiation Dose Aspects of Hepatic Artery Infusion Chemotherapy in Uveal Melanoma Patients with Liver Metastases.肝脏转移的葡萄膜黑色素瘤患者肝动脉化疗栓塞的辐射剂量方面。
Cardiovasc Intervent Radiol. 2022 Jun;45(6):841-845. doi: 10.1007/s00270-022-03130-1. Epub 2022 Apr 18.

本文引用的文献

1
The history of interventional therapy for liver cancer in China.中国肝癌介入治疗的历史。
J Interv Med. 2019 Apr 30;1(2):70-76. doi: 10.19779/j.cnki.2096-3602.2018.02.02. eCollection 2018 May.
2
Radiation dose reduction capabilities of a new C-arm system with optimized hard- and software.新 C 臂系统的辐射剂量降低功能,具有优化的硬件和软件。
Eur J Radiol. 2021 Jan;134:109367. doi: 10.1016/j.ejrad.2020.109367. Epub 2020 Nov 10.
3
Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
肝动脉灌注化疗与索拉非尼治疗晚期肝细胞癌的疗效比较
Liver Cancer. 2020 Sep;9(5):583-595. doi: 10.1159/000508724. Epub 2020 Jul 24.
4
Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies.肝细胞癌的局部区域治疗方法:最新进展与管理策略
Cancers (Basel). 2020 Jul 15;12(7):1914. doi: 10.3390/cancers12071914.
5
[Hepatocellular carcinoma].[肝细胞癌]
Pathologe. 2020 Sep;41(5):478-487. doi: 10.1007/s00292-020-00801-z.
6
Cancer burden of major cancers in China: A need for sustainable actions.中国主要癌症的癌症负担:需要采取可持续行动。
Cancer Commun (Lond). 2020 May;40(5):205-210. doi: 10.1002/cac2.12025. Epub 2020 May 2.
7
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.索拉非尼联合奥沙利铂、氟尿嘧啶和亚叶酸治疗伴有门静脉侵犯的肝细胞癌与索拉非尼单药治疗的随机临床试验。
JAMA Oncol. 2019 Jul 1;5(7):953-960. doi: 10.1001/jamaoncol.2019.0250.
8
Retrospective study of patients radiation dose during cardiac catheterization procedures.心脏导管插入术期间患者辐射剂量的回顾性研究。
Br J Radiol. 2019 Jul;92(1099):20181021. doi: 10.1259/bjr.20181021. Epub 2019 May 14.
9
Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.使用改良FOLFOX方案的肝动脉灌注化疗与经动脉化疗栓塞术治疗巨大不可切除肝细胞癌的前瞻性非随机研究。
Chin J Cancer. 2017 Oct 23;36(1):83. doi: 10.1186/s40880-017-0251-2.
10
Transarterial Therapies for Hepatocellular Carcinoma.肝细胞癌的经动脉治疗
Liver Cancer. 2016 Nov;6(1):27-33. doi: 10.1159/000449347. Epub 2016 Nov 29.